个人简介：

王俊，教授，研究员，博导，国家级青年人才项目入选者 (2023)。2016年毕业于中国科学院水生生物研究所并获得博士学位。于2018-2022年期间在北卡大学教堂山分校莱恩博格综合癌症中心从事博士后研究工作，2022年9月晋升为Research Associate，主要集中于致癌基因的转录调控机制研究。于2023年6月加盟南京大学现代生物研究院，并建立 “表观遗传调控与癌症靶向治疗（Epigenetic Regulation and Cancer Target Therapy）” 实验室。

王俊教授长期致力于研究表观遗传因子调控致癌基因异常表达的机理并且开发相应的癌症治疗方法。在基因转录调控与癌症靶向治疗领域取得了一系列原创性成果。包括 ① 首次发现和阐明在癌症中EZH2通过非经典功能即通过TAD结构域结合转录因子（TFs）以及p300（组蛋白乙酰转移酶）来激活基因表达和促进癌症发生的机理，并以EZH2为靶点设计小分子降解剂（PROTAC）药物，阐明其可以同时靶向EZH2经典和非经典功能的机制，为治疗EZH2依赖的癌症提供一种新的治疗方法（Nature Cell Biology 2022，一作; Nucleic Acids Research 2022，一作; Oncogene 2022，共一; IJMS 2020，一作）；② 此外首次发现组蛋白H3能够被羟基化产生一种全新的组蛋白修饰并命名为H3P16oh, 阐明其在细胞中调控基因表达的机理，通过将氧气感知通路和组蛋白修饰以及基因表达联系起来，为进一步研究组蛋白修饰在氧气感知通路的作用提供了新的研究思路 （Nature Genetics 2022，共一）。至今已经在Nature Cell Biology, Nature Genetics, Science, Science translational research, Molecular Cell, Nucleic Acids Research, Oncogene 等杂志发表SCI论文16篇，研究结果受广泛关注和报道。

研究方向：

实验室将围绕表观调控因子介导基因异常表达的调控机制开展研究，利用多组学技术（2D和3D基因组学）、蛋白质谱技术、CRISPR-sgRNA 筛选以及单细胞测序等技术，以小鼠为模型，探索表观遗传因子调控癌症发生发展的新分子机制，鉴定的新的癌症治疗靶点以及为癌症靶向治疗开发新的策略。

具体研究方向：

1)    探索表观遗传因子介导的基因转录调控新机制；

2) 探究表观遗传因子介导的肿瘤免疫逃逸机制；

3) 靶向表观遗传因子的癌症治疗药物开发。

代表性论文： (*Co-first author, #Corresponding author)

（全部论文详见： https://scholar.google.com/citations?view_op=list_works&hl=zh-CN&user=WPQaUFkAAAAJ ）

1. Wang J* , Yu X*, Gong W, Liu X, Park KS, Ma A, Tsai YH, Shen Y, Onikubo T, Pi WC, Allison DF, Liu J, Chen WY, Cai L, Roeder RG, Jin J#, Wang GG#. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat Cell Biol. 2022 Mar;24(3):384-399. PMID: 35210568.

2. Liu X*, Wang J* , Gong W, Zhao S, Zhang C, Wu Q, Jain K, Boyer JA, Guo Y, Rodriguez J, Li M, Uryu H, Liao C, Hu L, Zhou J, Shi X, Tsai YH, Yan Q, Luo W, Zhang Q, Strahl BD, Kriegsheim A, Wang GG, Baldwin AS, Zhang Q#. A Role for Histone H3 Proline 16 Hydroxylation in Regulation of Mammalian Gene Expression. Nature Genetics . 2022 Nov;54(11):1721-1735. PMID: 36347944. (https://doi.org/10.1038/s41588-022-01212-x, News & Views).

3. Jun Wang* , Kwang-Su Park*, Xufen Yu, Weida Gong, H. Shelton Earp, Gang Greg Wang#, Jian Jin# and Ling Cai#. A cryptic transactivation domain of EZH2 binds AR and its splice variant promoting oncogene activation and prostate tumorigenesis. tumorous transformation. Nucleic Acids Research , 50(19), 10929-10946. PMID: 36300627.

4. Yu X*, Wang J* , Gong W, Ma A, Shen Y, Zhang C, Liu X, Cai L, Liu J, Wang GG#, Jin J#. Dissecting and Targeting Noncanonical Functions of EZH2 in Multiple Myeloma via an EZH2 Degrader. Oncogene . 2023 Mar;42(13):994-1009. doi: 10.1038/s41388-023-02618-5. PMID: 36747009.

5. Wang J , Wang GG. No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function. Int J Mol Sci . (2020) Dec 14; 21(24):9501. PMID: 33327550.

6. Dardis GJ, Wang J , Simon JM, Wang GG, Baldwin AS. An EZH2-NF- κ B regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer. iScience . 2023 Jun 14;26(7):107115. doi: 10.1016/j.isci.2023.107115. PMID: 37416481.

7. Yu X*, Li D*, Kottur J*, Shen Y, Kim HS, Park KS, Tsai YH, Gong W, Wang J , Suzuki K, Parker J, Herring L, Kaniskan HÜ, Cai L, Jain R, Liu J, Aggarwal AK, Wang GG#, Jin J#. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Science Translational Medicine . 2021 Sep 29;13(613):eabj1578. PMID: 34586829.

8. Pi WC, Wang J , Shimada M, Lin JW, Geng H, Lee YL, Lu R, Li D, Wang GG, Roeder RG#, Chen WY#. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia. Blood . 2020 Jul 2;136(1):11-23. PMID: 32276273.

9. Xijuan Liu, Jeremy M. Simon, Haibiao Xie, Lianxin Hu, Jun Wang , Giada Zurlo, Cheng Fan, Travis S. Ptacek, Laura Herring, Xianming Tan, Mingjie Li, Albert S. Baldwin, William Y. Kim, Tao Wu, Marc W. Kirschner, Kan Gong, Qing Zhang. Genome-wide Screening Identifies SFMBT1 as a New Oncogenic Driver in Cancer with VHL Loss. Mol Cell , 2020 Mar 19: 77 (6): 1294-1306. PMID: 32023483.

10. Lu R, Wang J , Ren Z, Yin J, Wang Y, Cai L, Wang GG#. A model system for studying the DNMT3A hotspot mutation (DNMT3AR882) demonstrates a causal relationship between its dominant-negative effect and leukemogenesis. Cancer Res . 2019 Jul 15;79(14):3583-3594. PMID: 31164355.

11. Jing Zhang*, Tao Wu*, Jeremy Simon, Mamoru Takada, Ryoichi Saito, Cheng Fan, Xian-De Liu, Eric Jonasch, Ling Xie, Xian Chen, Xiaosai Yao, Bin Tean Teh, Patrick Tan, Xingnan Zheng, Mingjie Li, Cortney Lawrence, Jie Fan, Jiang Geng, Xijuan Liu, Lianxin Hu, Jun Wang , Chengheng Liao, Kai Hong, Giada Zurlo, Joel S. Parker, J. Todd Auman, Charles M. Perou, W. Kimryn Rathmell, William Y. Kim, Marc W. Kirschner, William G. Kaelin Jr., Albert S. Baldwin, Qing Zhang. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science , 2018 July 20; 361 (6399): 290-295. PMID: 30026228.

12. Cai L, Tsai YH, Wang P, Wang J , Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS#, Wang GG#. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell . 2018 Oct 18;72(2):341-354.e6. PMID: 30270106.

13. Wang, J. , Gui, L., Chen, ZY. et al. Mutations in the C-terminal region affect subcellular localization of crucian carp herpesvirus (CaHV) GPCR. Virus Genes . 2016 52, 484 – 494. PMID: 27059239.

联系邮箱 ：

[email protected]

欢迎相关学科背景或者感兴趣的学生申请攻读硕士/博士，也欢迎有兴趣的青年学者加入我们。